Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses

Data ReadoutpositiveDCVax-LPositive

AI Analysis

Summary

Northwest Biotherapeutics presented updated Phase III survival data for DCVax-L in glioblastoma at the British Neuro-Oncology Annual Meeting, with individual patient level analyses suggesting the original survival benefit analysis was likely underestimated.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

Updated survival data from Phase III trial presented; original analysis of survival extension was likely underestimated

Importance:7/10

Sentiment:

0.70

glioblastomaimmunotherapyPhase III datasurvival benefitscientific presentation

Related Companies

$NWBO

Read the original article

Published by PR Newswire Pharma on July 8, 2026 6:42 PM

Read Original